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Abstract 
Introduction 
Systemic sclerosis (SSc) is a connective tissue disorder characterised by the development of 
skin fibrosis. Our current understanding of the disease pathogenesis is incomplete and the 
study of SSc is hindered, at least partially, by a lack of animal models that fully replicate the 
complex state of human disease. Murine model of bleomycin-induced dermal fibrosis 
encapsulates important events that take place early in the disease course. 
Methods 
To characterise the optimum in vivo parameters required for the successful induction of 
dermal fibrosis we subjected three commonly used mouse strains to repeated subcutaneous 
bleomycin injections. We aimed to identify the effects of genetic background and gender on 
the severity of skin fibrosis. We used male and female Balb/C, C57BL/6, and DBA/2 strains 
and assessed their susceptibility to bleomycin-induced fibrosis by measuring dermal 
thickness, hydroxyproline/collagen content and number of resident myofibroblasts, all of 
which are important indicators of the severity of skin fibrosis. All data are expressed as mean 
values ± SEM. The Mann–Whitney U test was used for statistical analysis with GraphPad 
Prism 6.04 software. 
Results 
Dermal fibrosis was most severe in Balb/C mice compared to C57BL/6 and DBA/2 
suggesting that Balb/C mice are more susceptible to bleomycin-induced fibrosis. Analysis of 
the effect of gender on the severity of fibrosis showed that male Balb/C, C57BL/6, DBA/2 
mice had a tendency to develop more pronounced fibrosis phenotype than female mice. Of 
potential importance, male Balb/C mice developed the most severe fibrosis phenotype 
compared to male C57BL/6 and male DBA/2 as indicated by significantly increased number 
of dermal myofibroblasts. 
Conclusion 
Our study highlights the importance of genetic background and gender in the induction of 
murine dermal fibrosis. Robust and reproducible animal models of fibrosis are important 
research tools used in pharmacological studies which may lead to better understanding of the 
pathogenesis of fibrotic diseases and assist in identification of new drugs. 
Introduction 
Systemic sclerosis (SSc) is an autoimmune disorder characterised by progressive connective 
tissue fibrosis and life-threatening complications with high mortality and morbidity [1]. It has 
long been known that the level of available transforming growth factor-β (TGF-β), 
connective tissue growth factor and other profibrotic molecules in the dermis are critical for 
the development and sustaining of fibrosis in SSc [2]. Furthermore, dermal fibrosis in SSc is 
thought to be the result of activation and differentiation of fibroblasts into apoptosis resistant 
and α-smooth muscle actin (α-SMA)-positive myofibroblasts. Increased expression of 
myofibroblasts further stimulates the formation of extracellular matrix (ECM) leading to 
aberrant skin architecture and pathological tissue remodelling [3]. There are no mechanistic-
based therapies, such as pharmaceutical drugs on the market that prevent and control the 
progression of excessive ECM formation in SSc. Thus, there is an urgent need to better 
understand fibrosis, devise processes for manipulating ECM formation and reduce excessive 
collagen deposition. The ability to develop novel anti-fibrotic therapies and analyse their 
efficacy in proof-of-concept (POC) studies is partly impeded by limitations in currently 
available animal models used to study this disorder in vivo. The pathophysiology of SSc is 
complex and believed to be caused by multiple factors including vasculopathy, inflammation, 
and autoimmunity [4,5]. Not surprisingly, there is currently no animal model that perfectly 
mimics all the steps associated with the development of dermal fibrosis. Although several 
inducible and genetic models exist [4,5], not a single one of these models recapitulates all of 
the clinical features consistent with human SSc [3]. Murine model of bleomycin-induced 
dermal fibrosis is widely used to study the changes that take place in the early phase of the 
disease [6]. Bleomycin is a glycopeptide-derived anti-tumor antibiotic, which was first 
isolated from a culture broth of Streptomyces verticillus [7]. Bleomycin induces the release of 
reactive oxygen species, recruitment of inflammatory cells, which activate resident 
fibroblasts and stimulate ECM formation. Due to its profibrotic properties, subcutaneous 
bleomycin is used to induce local skin fibrosis known to persist for up to six weeks [8]. Apart 
from its local effect, high dose subcutaneous bleomycin injections are thought to induce lung 
fibrosis [7] and systemic autoimmune responses characterised by the presence of antinuclear 
autoantibodies, such as anti–Scl-70, anti–U1 RNP [9]. 
The model of bleomycin-induced skin fibrosis, originally described by Yamamoto [10], has 
been used widely in preclinical [11] and pharmacological studies [12]. Several modifications 
of this protocol exist raising the issue of study-to-study variance of the resulting dermal 
fibrosis. Given that bleomycin-induced model of SSc is an important tool in understanding 
the pathogenesis of fibrotic skin changes, we investigated the susceptibility and intensity of 
dermal fibrosis observed in mouse skin of three widely utilised mouse strains of both 
genders. We therefore hypothesised that different strains of mice will have various degrees of 
sensitivity in response to bleomycin-induced dermal fibrosis. The aim of this study was to 
suggest an optimised protocol and describe the methods necessary for the induction of 
standardised model of fibrosis in adult mouse skin. The observations of this study are to be 
used as a guide to finding a suitable animal model, which is morphologically and 
histologically consistent with early stages of SSc-associated skin fibrosis. 
Methods 
Murine model of bleomycin-induced dermal fibrosis 
Three mouse stains, namely Balb/C, C57BL/6, DBA/2 (Janvier, Genest-St-Isle, France), were 
used in the studies. Balb/C strain, originally created from a stock of outbred albino mice, was 
systematically inbred and has the following related genotype: Tyr
c
/ Tyr
c
, Tyrp1
b
/Tyrp1
b
, A 
/A - MHC: Haplotype H2
d
. The inbred strain of C57BL/6 mice (related genotype: a (a/a) non 
agouti - MHC: Haplotype H2
b
) is a widely used strain, which is frequently used as genetic 
background in transgenic models 
http://www.janvierlabs.com/tl_files/_media/images/FICHE_RESEARCH_MODEL_C57BL6
JRj.pdf. The DBA is the oldest of all inbred strains of mice, with the DBA/2 substrain having 
the following genotype: a/a, Tyrp1
b
/Tyrp1
b
, Myo5a
d
/Myo5a
d
 - MHC: Haplotype H2
d
. 
To determine whether gender and mouse strain have an influence on the severity of dermal 
fibrosis we subjected one group of male Balb/C (n=6), C57BL/6 (n=6), DBA/2 (n=6) mice of 
6 weeks of age, weighing 20–25 g to bleomycin injections at a concentration of 0.5 mg/ml. 
The upper dorsa of mice were shaved and one square measuring 1 cm
2
 was drawn on the 
midline using a marker. 100 μl of bleomycin (Laboratoire Roger Bellon, Neuilly-sur-Seine, 
France) at 0.5 mg/ml dissolved in PBS was administered every other day for 21 days. As part 
of the protocol, bleomycin injection sites were rotated. The first four injections were 
administered into four different corners of the square followed by the fifth injection given in 
the middle of the square. This protocol was continued until the day of post-mortem, at which 
point the marked square created on dorsal surface of mice was harvested, with one half of 
biopsy fixed in 4 % wt/vol. paraformaldehyde for histology and the other half snap frozen for 
molecular biology. 
Another group of female Balb/C (n=6), C57BL/6 (n=6), DBA/2 (n=6) was subjected to 
bleomycin injections (100 μl of bleomycin at 0.5 mg/ml, every other day for 21 days). Age-
matched control animals were treated with and equivalent dose of vehicle. Each experimental 
group consisted of 6 mice. 
In a separated experiment, we aimed to assess whether frequency of bleomycin injections had 
the capacity to alter the severity of dermal fibrosis. We subjected one group of male C57BL/6 
mice (n=6) of 6 weeks of age, weighing 20–25 g to bleomycin injections (0.5 mg/ml) given 
every day and another group (n=6) to bleomycin injections (0.5 mg/ml) given every other day 
for 21 days. In a different experiment, we endeavoured to determine the effect of bleomycin 
dosage (C57BL/6 mice, bleomycin at 0.5 mg/ml vs. 1 mg/ml administered every other day 
for 21 days) on the severity of dermal fibrosis. Mice were killed at 21 days after the first 
bleomycin experiment. 5 mm of lesional skin was harvested and fixed in 4 % wt/vol. buffered 
formalin and processed for histology. Four lesional skin biopsies (3 mm each) were snap 
frozen in liquid nitrogen and used for colorimetric assessment of collagen content 
(hydroxyproline assay). All animal experiments were approved by the local Animal Ethics 
Committee (Comité National de Réflexion Ethique sur l’Expérimentation Animale-34) and 
principles of laboratory animal care were followed. 
Histology, immunohistochemistry and image analysis 
Histological sections (4 μm) were cut from paraffin-embedded formalin fixed lesional skin 
tissue. Sections were stained with haematoxylin and eosin and images were captured at × 100 
microscopic magnification. Histological dermal thickness was determined by manually 
drawing a straight line between the epidermis and adipose layer. Image analysis was 
performed using the Image J (freely available Java image processing program). Blinded 
measurements of histological slides by two independent assessors was performed. 
4 μm paraffin-embedded formalin fixed samples of lesional skin were subjected to 
immunohistochemistry according to manufacturer’s protocol (Dako, Carpinteria, California, 
USA). Skin sections were deparaffinised and followed by antigen retrieval blocked in Super 
Block IDetect Super Stain System HRP (ID Labs, London ON N4A 5 K2, Canada) for 10 
minutes followed by incubation with 3 % H2O2 for 10 min to block endogenous peroxidase 
activity. Primary antibodies against α-SMA (1:500, Abcam), CD3 (1:50, Abcam), CD22 
(1:100, Abcam) and CD68 (1:100, Abcam) was applied overnight. Species-specific, 
biotinylated secondary antibodies (1:200) were used and detection was by Dako Liquid DAB 
Chromagen System (Dako, Carpinteria, California, USA). Myofibroblasts were identified by 
staining for α-SMA, as previously described [12]. The number of α-SMA, CD3, CD22 and 
CD68 positive cells was determined at high magnification in four different sections obtained 
from each mouse and determined by two blinded examiners. The number of α-SMA, CD3, 
CD22 and CD68 positive cells was counted and expressed as a number of total cells within 
each microscopic filed normalised against NaCl control as previously described [12]. 
Negative controls included replacing primary antibodies with normal species specific IgG. 
Assessment of inflammatory infiltrate 
Assessment of the number of infiltrating mononuclear/inflammatory cells in bleomycin and 
NaCl-treated mouse skin was determined using H&E stained sections as well as 
immunohistochemistry images of CD3, CD22 and CD68 stained skin as described previously 
[12]. Eight different high power fields from each mouse skin sections were evaluated for 
inflammatory infiltrate by two independent examiners blinded to the treatment. 
Multiphoton microscopy 
Multiphoton inverted stand Leica SP5 microscope (Leica Microsystems Gmbh, Wetzlar, 
Germany) was used for tissue imaging as previously described [13]. A Ti:Sapphire 
Chameleon Ultra (Coherent, Saclay, France) with a center wavelength at 810 nm was used as 
the laser source for generating second harmonic generation (SHG) and two-photon excited 
fluorescence signals (TPEF). The laser beam was circularly polarized and we used a Leica 
Microsystems HCX IRAPO 25x/0.95 W objective. SHG and TPEF signals were detected in 
epi-collection through a 405/15-nm and a 525/50 bandpass filters respectively, by NDD PMT 
detectors (Leica Microsystems) with a constant voltage supply, at constant laser excitation 
power, allowing direct comparison of SHG intensity values. LAS software (Leica, Germany) 
was used for laser scanning control and image acquisition. 
Masson’s trichrome staining 
For direct visualisation of collagen fibres and histological assessment of collagen deposition, 
trichrome staining was performed using the Masson Trichrome Staining Kit (Sigma-Aldrich, 
St Louis, MO, USA). Skin sections stained with Masson Trichrome were visualised at × 200 
microscopic magnification. All images were captured with Olympus BX63F microscope 
(Olympus, Tokyo, Japan) equipped with a digital signal processor CoolSNAP scientific CCD 
camera (Photometrics, Tucson, AZ, USA). 
Collagen measurements 
The collagen content in lesional skin samples was explored by hydroxyproline assay. After 
digestion of punch biopsies (3 mm) in 6 M HCl for three hours at 120 °C, the pH of the 
samples was adjusted to 7 with 6 M NaOH. Samples were then mixed with 0.06 M 
chloramine T and incubated for 20 min at room temperature. Next, 3.15 M perchloric acid 
and 20 % p-dimethylaminobenzaldehyde were added and samples were incubated for 
additional 20 min at 60 °C. The absorbance was determined at 557 nm with a Spectra MAX 
190 micro plate spectrophotometer (Molecular Devices, Sunnyvale, California, USA). 
Statistics 
All data are expressed as mean values ± SEM. The Mann–Whitney U test for non-related 
samples was used for statistical analysis with GraphPad Prism 6.04 software (San Diego, 
CA). A p value of less than 0.05 was considered statistically significant. 
Results 
Pro-fibrotic effects of subcutaneous bleomycin injections in the dermis of male 
Balb/C, C57BL/6 and DBA/2 mice 
To determine whether bleomycin had the same capacity to induce dermal fibrosis in three 
(Balb/C, C57BL/6 and DBA/2) inbred mouse strains that are frequently used for studies in 
the field of dermal fibrosis research, we administered bleomycin at a concentration of 0.5 
mg/ml, which was injected every other day for the period of 3 weeks. Assessment of dermal 
thickness, hydroxyproline content and myofibroblast count showed that bleomycin 
successfully induced dermal fibrosis in all of the three strains assessed (Fig. 1a-f). Bleomycin 
treatment in Balb/C, C57BL/6 and DBA/2 mice was associated with an increase in dermal 
thickness by 19.89 %, 21.31 % and 18.7 % respectively when compared to NaCl-treated 
counterparts (Fig. 1b). No significant difference in dermal thickness was found between 
bleomycin treated male Balb/C, C57BL/6 and male DBA/2 mice (Fig. 1b). To confirm that 
the observed increase in dermal thickness in bleomycin-treated skin was due to increased 
collagen content, type I fibrillary collagen has been imaged by SHG (Fig. 1c) and 
hydroxyproline assay (Fig. 1d) were performed. Note similar baseline distribution of collagen 
fiber alignment in NaCl-treated Balb/C, C57BL/6 and DBA/2 mice (Fig. 1c, d). Consistent 
with increased dermal thickness in bleomycin treated groups, increased accumulation of 
collagen was observed in Balb/C, C57BL/6 and DBA/2 skin when compared to NaCl-treated 
controls (Fig. 1c; p = 0.0290 in Balb/C; p = 0.0001 in C57BL/6; p = 0.0103 in DBA/2). 
Fig. 1 Histological and histochemical analysis of dermal fibrosis in male bleomycin-treated 
Balb/C, C57BL/6 and DBA/2 mice. a Representative images of H&E-stained sections of 
male mouse skin treated with subcutaneous NaCl or bleomycin given every other day over a 
period of 3 weeks. Original magnification ×100. b Graphical representation of dermal 
thickness of skin harvested from mice treated with NaCl or bleomycin after 3 weeks. Four 
high power field images were taken (2 measurements per image). Results represent the 
relative fold change compared to NaCl-treated control mice. All values represent means 
±SEM; n=6 each group. c Representative images of SHG imaging of type I fibrillary collagen 
in mouse skin harvested after 3 weeks of treatment with NaCl or bleomycin injected every 
other day. Note different distribution of fiber alignment and intensity in NaCl and bleomycin 
treated samples. We note that all images were acquired with the same excitation power. 
Original magnification ×250. d Graphical representation of hydroxyproline assay. Results are 
represented as means ±SEM of triplicate measurements obtained from 6 mice (2 biopsies per 
mouse) and shown as relative fold change compared to NaCl-treated control samples. e 
Representative images of α-SMA immunohistochemistry. Original magnification ×200, inset 
×630. f Graphical representation of relative number of α-SMA-positive cells in dermis of 
NaCl or bleomycin-treated mice. Results represent the relative fold change compared to 
NaCl-treated control mice. All values represent means ±SEM; n=6 each group 
Increased levels of collagen content in bleomycin treated skin may result from increased 
recruitment of myofibroblasts. In order to determine whether myofibroblasts contributed to 
increased levels of collagen in the dermis of male Balb/C, C57BL/6 and DBA/2 mouse skin, 
we analysed the number of myofibrolbasts (Fig 1e-f). Under fibrotic conditions myofibroblast 
count increased by 5-fold in male Balb/C compared to NaCl control, by 2-fold in male 
C57BL/6 and 3-fold in male DBA/2 mice. Male Balb/C mice treated with bleomycin showed 
significantly increased count of dermal myofibroblasts compared to bleomycin-treated male 
C57BL/6 mice (p = 0.0041) and DBA/2 mice (p = 0.05) (Fig 1f). 
Female Balb/C mice are more ‘susceptible’ to bleomycin-induced dermal 
fibrosis than female C57BL/6 and DBA/2 counterparts 
Dermal fibrosis was induced in female Balb/C, C57BL/6 and DBA/2 via subcutaneous 
bleomycin injections given for 3 weeks at a final concentration of 0.5 mg/kg and given every 
other day. Histological changes were determined by measuring the length of dermal thickness 
in bleomycin-treated and NaCl control female Balb/C, C57BL/6 and DBA/2 mice. Dermal 
thickness was determined by measuring the average thickness between the epidermal-dermal 
and dermal–subcutaneous fat junctions. 
Bleomycin treatment resulted in an increase of dermal thickness in female Balb/C mice 
compared to NaCl-treated female Balb/C mice (Fig. 2b; p = 0.0001). No significant 
difference was observed in dermal thickness of bleomycin-treated female C57BL/6 mice 
compared to NaCl-treated female controls (Fig. 2b), however there was a 43.7 % (p=0.0036) 
increase in collagen content and 33.8 % increase (p=0.0136) in myofibroblast count in female 
C57BL/6 mice compared to NaCl-treated female controls (Fig. 2c-d). There was no 
significant change in dermal thickness, hydroxyproline content and myofibroblast count in 
female DBA/2 mice treated with bleomycin compared to female DBA/2 mice treated with 
NaCl (Fig. 2a-f). 
Fig. 2 Female Balb/C mice are more susceptible to bleomycin-induced dermal fibrosis than 
female C57BL/6 and DBA/2 mice. a Representative images of H&E-stained sections of 
female mouse skin treated with subcutaneous NaCl or bleomycin injections given every other 
day over a period of 3 weeks. Original magnification ×100. b Graphical representation of 
dermal thickness of female mouse skin harvested from mice treated with NaCl or bleomycin 
after 3 weeks. Four high power field images were taken (2 measurements per image). Results 
represent the relative fold change compared to NaCl-treated control mice. c Representative 
images of SHG imaging of type I fibrillary collagen in mouse skin harvested after 3 weeks of 
treatment with NaCl or bleomycin injected every other day. Original magnification ×250. d 
Graphical representation of hydroxyproline assay. Results are represented as means ±SEM of 
triplicate measurements obtained from 6 mice (2 biopsies per mouse) and shown as relative 
fold change compared to NaCl-treated control samples. e Representative images of α-SMA 
immunohistochemistry. Original magnification ×200, inset ×630. f Graphical representation 
of relative number of α-SMA-positive cells in dermis of NaCl or bleomycin-treated mice. 
Results represent the relative fold change compared to NaCl-treated control mice. All values 
represent means ±SEM; n=6 each group 
Effect of gender on the induction of experimental dermal fibrosis 
To study the effect of gender on the induction of dermal fibrosis we compared fibrotic 
phenotype as determined by three parameters: dermal thickness, hydroxyproline content and 
myofibroblast count. Although male Balb/C and male C57BL/6 mice have scored higher in 
histological and immunohistochemical analysis of bleomycin treated skin, there was no 
significant difference in dermal thickness, hydroxyproline and myofibroblast count between 
male and female Balb/C and C57BL/6 mice (Fig. 3a-c). The number of myofibroblasts in 
male DBA/2 mice was significantly higher than in female DBA/2 mice (Fig. 3c; p=0.0355). 
Fig. 3 Gender effects the severity of dermal fibrosis and inflammatory response. a 
Bleomycin-treated male Balb/C and male DBA/2 mice have slightly higher dermal thickness 
and b hydroxyproline content compared to their female counterparts, however this number 
doesn’t reach significance. c Bleomycin-treated male DBA/2 mice have significantly higher 
myofibroblasts than their female counterparts. d Representative images of H&E-stained 
sections of male Balb/C, C57BL/6 and DBA/2 skin subjected to bleomycin (0.5 mg/ml) 
injections given every other day. e Graphical representation of relative number of 
inflammatory cells in dermis of male Balb/C, C57BL/6 and DBA/2 in response to bleomycin 
injections. f Representative images of H&E-stained sections of female Balb/C, C57BL/6 and 
DBA/2 skin subjected to bleomycin (0.5 mg/ml) injections given every other day. g 
Graphical representation of relative number of inflammatory cells in dermis of female 
Balb/C, C57BL/6 and DBA/2 in response to bleomycin injections. Original magnification 
×630. All values represent means ±SEM; n=6 each group 
Male DBA/2 mice have the lowest number of infiltrating leukocytes 
In addition to fibrotic skin changes, repetitive bleomycin injections are known to cause skin 
inflammation as defined by increased number of leukocytes recruited to the lesional area [7]. 
To determine whether the type of mouse strain had an effect on the number of inflammatory 
cells and the rate of inflammation in bleomycin-treated skin (0.5 mg/ml, alternate days, 3 
weeks), male and female Balb/C, C57BL/6 and DBA/2 skin was stained with H&E and the 
number of leukocytes was counted (Fig. 3d and e). The number of leukocytes in bleomycin-
treated male Balb/C and C57BL/6 skin was 2.1 and 2.5-fold higher respectively than in 
bleomycin-treated male DBA/2 mice (Fig. 3d and e; p=0.0142 and p=0.0018 respectively). 
The type of mouse strain did not have an effect on the rate of inflammation in females since 
there was no significant difference in the number of leukocytes between female Balb/C, 
female C57BL/6 and female DBA/2 mice (Fig. 3e and g). 
To identify the nature of infiltrating leucocytes and determine the influence of mouse strain 
on leucocyte infiltration, we next quantified the number of CD3, CD22 and CD68 positive 
cells in male and female Balb/C, C57BL/6 and DBA/2 skin. The number of CD3, CD22 and 
CD68 positive cells were significantly reduced in male DBA/2 bleomycin-treated skin 
compared to bleomycin treated male Balb/C and C57BL/6 skin (Fig. 4a-f). There appeared to 
be no difference between the number of CD3, CD22 and CD68 positive cells in bleomycin 
challenged female Balb/C, C57BL/6 and DBA/2 skin. (Fig. 4g-l). 
  
Fig. 4 Male DBA-2 mice showed reduced number of CD3, CD22 and CD68 cell infiltration 
into bleomycin challenged mouse skin. Representative images of (a) CD3, (b) CD22 and (c) 
CD68 immunohistochemistry sections of male Balb/C, C57BL/6 and DBA/2 skin subjected 
to bleomycin (0.5 mg/ml) injections given every other day. d-f Graphical representation of 
relative number of CD3, CD22 and CD68 positive cells in dermis of male Balb/C, C57BL/6 
and DBA/2 in response to bleomycin injections. Original magnification ×400. All values 
represent means ±SEM; n=6 each group. Representative images of (g) CD3, (h) CD22 and (i) 
CD68 immunohistochemistry sections of female Balb/C, C57BL/6 and DBA/2 skin subjected 
to bleomycin (0.5 mg/ml) injections given every other day. (j-l) Graphical representation of 
relative number of CD3, CD22 and CD68 positive cells in dermis of female Balb/C, C57BL/6 
and DBA/2 in response to bleomycin injections. Original magnification ×400. All values 
represent means ±SEM; n=6 each group 
Effect of frequency of bleomycin administration on the severity of mouse skin 
fibrosis 
To establish whether the frequency of bleomycin injections had an effect on the severity of 
skin fibrosis, male C57BL/6 mice were given daily subcutaneous injections of bleomycin (at 
0.5 mg/ml, 3 weeks) and compared to male C57BL/6 mice which were given bleomycin 
injections on alternate days (at 0.5 mg/ml, 3 weeks). In response to bleomycin, which was 
given either daily or on alternate days, dermal thickness increased in bleomycin-treated mice 
compared to NaCl-treated controls (Fig. 5a and b). Although there was no difference in 
dermal thickness between mice treated with bleomycin daily or on alternate day (Fig. 5b), 
collagen accumulation as determined by hydroxyproline content (Fig. 5d, p=0.0173) was 
significantly elevated in mice treated with bleomycin on alternate days compared to those 
treated every day. While myofibroblast count was slightly higher in mice treated with 
bleomycin on alternate days compared to those treated every day, this number did not reach 
significance (Fig. 5f). 
Fig. 5 Male C57BL/6 mice subjected to bleomycin injections on alternate days show higher 
dermal collagen content than male C57BL/6 mice given daily bleomycin injections. a 
Representative images of H&E-stained sections of male C57BL/6 mouse skin treated with 
subcutaneous NaCl or bleomycin injections given either daily or every other day over a 
period of 3 weeks. Original magnification ×100. b Graphical representation of dermal 
thickness of male C57BL/6 mouse skin treated with subcutaneous NaCl or bleomycin 
injections given either daily or every other day over a period of 3 weeks. Four high power 
field images were taken (2 measurements per image). Results represent the relative fold 
change compared to NaCl-treated control mice. c Representative images of Masson’s 
Trichrome-stained sections of mouse skin harvested after 3 weeks of treatment with NaCl or 
bleomycin injected either every day or every other day. Original magnification ×100. d 
Graphical representation of hydroxyproline assay which was used as an indicator of collagen 
content in mouse skin treated with bleomycin every day vs. alternate days. Results are 
represented as means ±SEM of triplicate measurements obtained from 6 mice (2 biopsies per 
mouse) and shown as relative fold change compared to NaCl-treated control samples. e 
Representative images of α-SMA immunohistochemistry. Original magnification ×200, inset 
×630. f Graphical representation of relative number of α-SMA-positive cells in dermis of 
mice treated with NaCl or bleomycin wither every day or alternate days. Results represent the 
relative fold change compared to NaCl-treated control mice. All values represent means 
±SEM; n=6 each group 
Increasing bleomycin concentration from 0.5 mg/ml to 1 mg/ml does not 
increase collagen deposition and myofibroblast accumulation in dermal 
fibrosis 
Male C57BL/6 mice were given subcutaneous injections of bleomycin at a final 
concentration of 0.5 mg/ml or 1 mg/ml (alternate days, 3 weeks). Increasing bleomycin 
concentration from 0.5 mg/ml or 1 mg/ml did not have an effect on the severity of dermal 
fibrosis. No difference in dermal thickness (Fig. 6a, b), hydroxyproline content (Fig. 6c, d) 
and myofibroblast count (Fig. 6e, f) was found between mouse skin injected with bleomycin 
at 0.5 mg/ml vs. 1 mg/ml. 
Fig. 6 The effect of low (0.5 mg/ml) and high (1 mg/ml) dosage of subcutaneous bleomycin 
injections on dermal thickness, collagen content and number of myofibroblasts in the skin of 
male C57BL/6 mice subjected to bleomycin on alternate days for 3 weeks. a Representative 
images of H&E-stained sections of male C57BL/6 mouse skin treated with subcutaneous 
NaCl or bleomycin injections (0.5 mg/ml or 1 mg/ml) given every other day for 3 weeks. 
Original magnification ×100. b Graphical representation of dermal thickness of male 
C57BL/6 mouse skin treated with subcutaneous NaCl or bleomycin injections (0.5 mg/ml or 
1 mg/ml) given every other day for 3 weeks. Four high power field images were taken (2 
measurements per image). Results represent the relative fold change compared to NaCl-
treated control mice. c Representative images of Masson’s Trichrome-stained sections of 
mouse skin harvested after 3 weeks of treatment with NaCl or bleomycin injections (0.5 
mg/ml or 1 mg/ml) given every other day for 3 weeks. Original magnification ×100. d 
Graphical representation of hydroxyproline content in skin treated with low and high (0.5 
mg/ml or 1 mg/ml) dosages of bleomycin. Results are represented as means ±SEM of 
triplicate measurements obtained from 6 mice (2 biopsies per mouse) and shown as relative 
fold change compared to NaCl-treated control samples. e Representative images of α-SMA 
immunohistochemistry in mouse skin treated with subcutaneous NaCl or bleomycin 
injections (0.5 mg/ml or 1 mg/ml) given every other day for 3 weeks. Original magnification 
×200, inset ×630. f Graphical representation of relative number of α-SMA-positive cells in 
dermis of mice treated with NaCl or bleomycin (0.5 mg/ml vs. 1 mg/ml) on alternate days. 
Results represent the relative fold change compared to NaCl-treated control mice. All values 
represent means ±SEM; n=6 each group 
Discussion 
Bleomycin-treated Balb/C mice have the most severe fibrosis phenotype compared to 
C57BL/6 and DBA/2 suggesting that the severity of skin fibrosis, apart from other factors 
such as the route of administration and dose of bleomycin [14], also depends on genetic 
background of mice. Male Balb/C mice showed a greater number of myofibroblasts than 
C57BL/6 and DBA/2 of the same gender. Female Balb/C mice were previously shown to 
have higher susceptibility to bleomycin with greater dermal thickness measurements than 
their female C57BL/6 and DBA/2 counterparts [14]. Similarly, in this study female Balb/C 
mice showed greater levels of skin fibrosis characterised by increased dermal thickness, 
greater deposition of collagen and elevated number of dermal myofibroblasts, suggesting 
that, at least in the females, Balb/C mice may be more susceptible to bleomycin-induced skin 
fibrosis than their C57BL/6 and DBA/2 counterparts. 
To determine the effect of gender on the severity of skin fibrosis, Balb/C, C57BL/6 and 
DBA/2 mice of both genders were used to induce and assess the extent of fibrosis. Male mice 
tended to have a more pronounced fibrosis phenotype than females and, as observed in 
DBA/2 mice, had significantly elevated number of myofibroblasts than female C57BL/6 and 
DBA/2 mice. The fact that male mice are more susceptible to the development of SSc-
associated skin fibrosis is in agreement with the epidemiological observations which suggest 
that although women have increased susceptibility to SSc than men, males are known to have 
a more severe skin fibrosis phenotype [3,15]. Age is another factor which may have impacted 
our study. Human studies indicate that most women are diagnosed with SSc later in life and 
generally after the onset of menopause [16], whereas animals used in the current study were 
young and sexually active mice of both genders. Therefore, differences in the severity of 
fibrosis observed between the genders were possibly due to age, which in turn is 
characterised by differential expression of sex hormones. For instance, oestrogen was 
previously shown to have an influence on the development of SSc-associated fibrosis [17] 
with low levels of oestrogen being associated with severe fibrosis and exacerbated pulmonary 
hypertension [17]. In women oestrogens are at their lowest after the menopause and highest 
during pregnancy. Given that most women are diagnosed with SSc at the time when their 
oestrogen levels are at their lowest [16] and some autoimmune diseases, including 
rheumatoid arthritis [18] go into remission when oestrogens are at their peak, suggests that 
oestrogen may play an important protective role in autoimmune diseases such as SSc. 
Consistent with the observations in human SSc, increased circulating levels of oestrogen in 
young female compared to young male mice may have had a protective effect against the 
development of fibrosis offering a plausible explanation as to why male mice developed a 
more severe fibrosis phenotype than female mice. 
Studying the characteristics of skin changes that develop as a result of repetitive bleomycin 
injections [10] can help to better understand inflammation and fibrosis, both of which are key 
elements that recapitulate the pathological events of SSc. Increased inflammatory infiltrate in 
lesional SSc skin, predominantly CD4+ T cells [19], suggests a distinct role of CD4 
lymphocytes in the development of skin fibrosis. In animal experiments, bleomycin evokes 
pro-inflammatory response and increased prevalence of leukocytes. Due to its complexity and 
the involvement of multiple organs, SSc is difficult to replicate in vivo. While many animal 
models of SSc exist [4] there is currently no animal model that can capture this complexity. 
Along with its disadvantages, namely the absence of vascular complications [5], bleomycin-
induced model of skin fibrosis provides us with an opportunity to study inflammation, 
elucidate the pathophysiology of SSc and explore potential treatment interventions. 
Inflammatory cells are thought to contribute to the initial activation of resident fibroblasts by 
the release of profibrotic mediators. To assess the contribution of genetic background on the 
development of inflammation associated with dermal fibrosis, Balb/C, C57BL/6 and DBA/2 
of both genders were treated for 3 weeks with subcutaneous injection of bleomycin. Given 
that male DBA/2 mice showed the least number of CD3, CD22 and CD68 positive 
inflammatory cells, we suggest that in studies that focus on investigating the effect of 
inflammation on the pathogenesis of dermal fibrosis, strains other than DBA/2 are used. The 
number of inflammatory cells in bleomycin-treated male C57BL/6 mice was three times as 
much as the number of leucocytes found in DBA/2 mice, suggesting that C57BL/6 could be a 
strain of choice in studies concerning inflammation. 
Having established the fact that male mice are more susceptible to dermal fibrosis than 
females we used male C57BL/6 mice to investigate if varying the frequency of bleomycin 
injections (every day versus alternate days) will have an effect on the severity of dermal 
fibrosis. Bleomycin stimulates extracellular matrix formation by virtue of its profibrotic 
effects, and of importance, our studies indicated that daily exposure to bleomycin blunted the 
pro-fibrotic response of bleomycin in the skin, whereas alternate day administration enhanced 
this effect. Bleomycin injections administered on alternate days resulted in increased basal 
hydroxyproline, a biochemical marker of collagen, compared to daily injections. Local 
bleomycin injections are associated with active stimulation of leukocyte infiltration [20] 
driving the release of a plethora of proinflammatory cytokines including TGF-β1, which in 
turn promotes the synthesis and secretion of collagen and other matrix molecules [21]. 
Enhanced immune response and consequent TGF-β activation aggravate fibrosis, as it sets up 
a positive-feedback which could partially explain the reason why bleomycin injections given 
on alternate days are more efficient in stimulating the extracellular matrix. Alternate day 
injections may cause peaks of cytokine release in the skin and stimulate a more sustained 
inflammatory response than bleomycin injections given daily. The frequent peaks of 
proinflammatory cytokine release induced by bleomycin injections administered on 
alternated days versus daily injections might be important in mediating an efficient 
profibrotic effect of bleomycin. Bleomycin increased skin collagen levels in a dose-
dependent manner and, although doses ≤ 0.5 mg/ml were reported to induce histological 
changes [10], our studies suggested that fibrotic responses were similar in mice treated with 
low (0.5 mg/ml) and high (1 mg/ml) doses of bleomycin. 
Conclusions 
In this study we evaluated the potential for mouse genetic background and gender to effect 
the induction of experimental mouse dermal fibrosis. With the information present herein, we 
suggest that dermal fibrosis studies are best done in male rather than female mice due to 
higher responsiveness to bleomycin injections. In C57BL/6 strain optimum results are 
obtained when treated with subcutaneous bleomycin at a final concentration of 0.5 mg/ml and 
administered on alternate days. These observations are of considerable importance with 
regard to the selection of an appropriate protocol necessary for the induction of dermal 
fibrosis, which may be used in pharmacological testing and therapeutical interventions. 
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